GON7 Antibody

What is GON7 and why is it significant in research?

GON7 (also known as C14orf142) is a protein of interest in human cellular biology. It functions as a component of the KEOPS complex involved in tRNA modification. Understanding GON7's expression patterns and interactions requires specific antibodies validated for research applications. The antibody against human GON7 enables researchers to study its expression patterns, cellular localization, and potential roles in various biological processes . Research using GON7 antibodies typically employs techniques such as immunohistochemistry (IHC), immunocytochemistry-immunofluorescence (ICC-IF), and Western blotting (WB) to investigate this protein's functions.

What validation techniques confirm GON7 antibody specificity?

Rigorous validation is essential for ensuring antibody specificity. For GON7 antibodies, the gold standard validation approach involves using knockout cell lines as negative controls. This methodology, as demonstrated in large-scale antibody validation studies, allows researchers to confidently determine whether bands detected in Western blots represent authentic GON7 protein or non-specific binding .

The following table outlines the recommended validation approaches for GON7 antibodies:

Which applications are GON7 antibodies validated for?

Commercially available GON7 antibodies undergo validation for specific applications. The rabbit polyclonal GON7 antibody from Atlas Antibodies, for example, is validated for immunohistochemistry (IHC), immunocytochemistry-immunofluorescence (ICC-IF), and Western blot (WB) applications . During experimental design, researchers should confirm that their selected antibody has been specifically validated for their intended application.

What is the recommended antibody concentration for different applications?

GON7 antibodies are typically available at concentrations such as 0.1 mg/ml , but the optimal working dilution varies by application. The table below provides general guidelines for GON7 antibody applications:

How can knockout validation improve GON7 antibody experimental design?

Knockout validation represents a critical approach for confirming antibody specificity. Large-scale antibody validation studies have demonstrated that comparing antibody performance between parental and knockout cell lines provides definitive evidence of specificity . For GON7 antibody experiments, implementing this validation approach involves:

• Developing GON7 knockout cell lines using CRISPR-Cas9 or similar gene editing technologies

• Running parallel experiments with wild-type and knockout cells

• Analyzing band patterns in Western blots to identify true GON7 signals versus non-specific binding

• Documenting this validation comprehensively in research publications

In studies where developing knockout lines is infeasible, alternative approaches include using published knockout validation data, siRNA knockdown validation, or comparing results across multiple antibodies targeting different GON7 epitopes.

What approaches help resolve contradictory results when using different GON7 antibodies?

When different GON7 antibodies yield inconsistent results, a systematic troubleshooting approach is essential. Contradictory results often stem from differences in epitope recognition, specificity, or technical factors. Researchers should:

• Compare the epitopes recognized by each antibody (N-terminal, C-terminal, or internal domains)

• Assess validation documentation for each antibody, prioritizing those with knockout validation

• Evaluate whether post-translational modifications might affect epitope recognition

• Consider whether splice variants of GON7 might explain differential recognition patterns

• Implement side-by-side testing under identical conditions with appropriate positive and negative controls

Standardized validation approaches similar to those used in comprehensive antibody assessment studies can help resolve such contradictions by systematically evaluating each antibody's specificity and sensitivity .

How do different fixation methods affect GON7 antibody performance in immunohistochemistry?

Fixation methods significantly impact antibody performance in immunohistochemistry and immunocytochemistry. For GON7 antibodies, researchers should consider:

Optimization experiments comparing these fixation methods are recommended when establishing new GON7 immunostaining protocols.

What is the recommended protocol for Western blot using GON7 antibodies?

For optimal Western blot results with GON7 antibodies, the following protocol is recommended:

• Sample preparation:

  • Lyse cells in RIPA buffer supplemented with protease inhibitors

  • Quantify protein concentration (BCA or Bradford assay)

  • Prepare samples (20-40 μg total protein) in reducing Laemmli buffer

  • Heat samples at 95°C for 5 minutes

• Gel electrophoresis and transfer:

  • Separate proteins on 10-12% SDS-PAGE gels

  • Transfer to PVDF membranes (nitrocellulose is a suitable alternative)

  • Verify transfer efficiency with Ponceau S staining

• Immunodetection:

  • Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Incubate with GON7 antibody (typically 1:1000 dilution) overnight at 4°C

  • Wash 3× with TBST, 5 minutes each

  • Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

  • Wash 3× with TBST, 5 minutes each

  • Develop using ECL substrate and appropriate imaging system

• Controls:

  • Include positive control (cell line known to express GON7)

  • Include negative control (GON7 knockout cells if available)

  • Use loading control (GAPDH, β-actin, or similar housekeeping protein)

How can I optimize immunoprecipitation protocols with GON7 antibodies?

Immunoprecipitation (IP) with GON7 antibodies allows for the isolation of GON7 and its interaction partners. For optimal results:

• Pre-clearing lysate:

  • Incubate cell lysate with protein A/G beads for 1 hour at 4°C

  • Remove beads by centrifugation to reduce non-specific binding

• Antibody binding:

  • Add 2-5 μg of GON7 antibody to 500 μg of pre-cleared lysate

  • Incubate overnight at 4°C with gentle rotation

• Immunocapture:

  • Add 30-50 μl of protein A/G beads

  • Incubate for 2-4 hours at 4°C with gentle rotation

  • Wash beads 4-5 times with cold lysis buffer

• Elution and analysis:

  • Elute proteins by boiling in Laemmli buffer

  • Analyze by Western blot using verified antibodies

• Controls:

  • Include an isotype control antibody IP

  • Analyze input, unbound, and IP fractions

  • Consider using knockout cells as negative controls

What are the key methodological controls when using GON7 antibodies?

Proper controls are essential for generating reliable data with GON7 antibodies. Based on standardized antibody validation approaches, researchers should implement the following controls :

How should I quantify and normalize GON7 expression data?

Accurate quantification of GON7 expression requires appropriate normalization and statistical analysis. Recommended approaches include:

• For Western blot quantification:

  • Use densitometry to measure band intensity

  • Normalize GON7 signal to loading controls (GAPDH, β-actin, total protein)

  • Include biological replicates (n≥3) for statistical analysis

  • Report data as fold change relative to control conditions

• For immunofluorescence quantification:

  • Measure average fluorescence intensity within defined cellular regions

  • Normalize to cell area or nuclear staining

  • Analyze sufficient cell numbers (typically >30 cells per condition)

  • Use appropriate statistical tests (t-test, ANOVA) based on data distribution

• For flow cytometry:

  • Report median fluorescence intensity rather than mean

  • Use fluorescence-minus-one controls for gating

  • Normalize to unstained or isotype controls

• For immunohistochemistry:

  • Use standardized scoring systems (H-score, Allred score)

  • Blind scorers to experimental conditions

  • Implement positive and negative tissue controls

How can I determine the appropriate antibody concentration for my specific application?

Determining optimal antibody concentration requires systematic titration experiments. For GON7 antibodies, which are typically supplied at concentrations around 0.1 mg/ml , consider:

• Titration strategy:

  • Start with manufacturer's recommended dilution

  • Test 3-5 dilutions spanning 2-3 orders of magnitude

  • Include positive and negative controls at each dilution

• Evaluation criteria:

  • Signal-to-noise ratio (specific vs. non-specific signal)

  • Consistency across replicate samples

  • Minimal background in negative controls

• Application-specific considerations:

  • Western blot: 1:500-1:5000 dilution range

  • IHC/ICC: 1:50-1:500 dilution range

  • Flow cytometry: 1:50-1:200 dilution range

• Documentation:

  • Record lot number and dilution in laboratory notebooks

  • Document optimization experiments for reproducibility

How do I account for cell-type specific expression patterns when interpreting GON7 results?

GON7 expression may vary significantly across cell types. To account for this heterogeneity:

• Reference datasets:

  • Consult protein atlases and transcriptomic databases for expected expression patterns

  • Compare your findings with published literature on GON7 expression

• Cell type markers:

  • Co-stain for cell type-specific markers alongside GON7

  • Use multiplexed approaches to correlate GON7 expression with cell identity

• Single-cell approaches:

  • Consider single-cell analysis techniques to resolve heterogeneous populations

  • Use flow cytometry or single-cell sequencing to correlate GON7 with cell states

• Controls and calibration:

  • Include multiple cell types with known GON7 expression levels

  • Use standardized positive controls across experiments

What strategies can resolve high background in GON7 immunostaining?

High background in GON7 immunostaining can compromise data interpretation. Systematic troubleshooting approaches include:

• Antibody-related adjustments:

  • Further dilute primary antibody

  • Reduce incubation time or temperature

  • Try alternative GON7 antibodies validated for the application

• Blocking optimizations:

  • Increase blocking reagent concentration (5-10% BSA or serum)

  • Extend blocking time (2-3 hours or overnight)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

• Washing modifications:

  • Increase number and duration of wash steps

  • Use detergent (0.05-0.1% Tween-20) in wash buffers

  • Consider using automated washers for consistency

• Sample preparation improvements:

  • Optimize fixation conditions

  • Consider antigen retrieval methods

  • Fresh preparation of all solutions

Validation studies of antibodies against various targets, including those using knockout controls, highlight the importance of these optimization steps for reducing background interference .

How should discrepancies in molecular weight detection be interpreted with GON7 antibodies?

When GON7 antibodies detect bands at unexpected molecular weights:

• Potential biological explanations:

  • Post-translational modifications (phosphorylation, glycosylation)

  • Splice variants or isoforms

  • Proteolytic processing

  • Protein complexes (if samples not fully denatured)

• Technical considerations:

  • Confirm protein ladder calibration

  • Validate with knockout controls to identify true GON7 bands

  • Compare detection patterns across multiple GON7 antibodies

• Verification approaches:

  • Mass spectrometry identification of unexpected bands

  • Immunoprecipitation followed by Western blot

  • Treatment with phosphatases or glycosidases to assess modifications